CtrlK
PFE
NYSE
Pharmaceuticals
$23.67
USD
-$0.49 (-2.01%)
Last close
Market Cap:
$136.96B
Volume:
57.1M
Previous Close
$24.16
Day Range
$23.62 - $24.34
52 Week Range
$23.11 - $28.75
Average Volume (10 Days)
53.2M
P/E Ratio
17.63
Dividend Yield
7.14%
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 75,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
CEO
Dr. Albert Bourla
Headquaters
New York City, NEW YORK, US
Founded
1944
Employees
75,000
Pfizer (PFE) closed the most recent trading day at $26.14, moving +2.11% from the previous trading session.
Pfizer (NYSE:PFE) is in the middle of its biggest reinvention in a generation, leaning on the Seagen oncology platform and the freshly closed Metsera obesity assets to offset a COVID revenue cliff and looming patent losses. With shares at $25.60 and yielding nearly 7%, the only question that matters for income investors is whether that ... This $25 Billion Acquisition Just Unlocked a New Era of Growth for Pfizer — and Why It’s a Flawless Safe-Haven for Retirees
At $25.60, Pfizer (NYSE:PFE) sits in Hold territory on Wall Street’s consensus. The headline 6.7% dividend yield is reason to pause rather than pounce. A payout that fat usually reflects a market pricing in trouble, and the under-the-radar concern is whether stretched operating cash flow can fund both the dividend and the debt stack from ... A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Thursday and uncover the stocks that are leading the way in terms of trading volume and market attention.
Before the stock surged, management was laying out a multi-billion-dollar growth story that directly contradicted consensus estimates, if you knew where to look.
ELAN
Elanco Animal Health Inc
$24.37
+1.6%
